Opsona Therapeutics Ltd.
🇮🇪Ireland
- Country
- 🇮🇪Ireland
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.opsona.com
Clinical Trials
23
Active:17
Completed:6
Trial Phases
2 Phases
Phase 1:15
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (83.3%)Phase 2
3 (16.7%)Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Opsona Therapeutics Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03337451
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Opsona Therapeutics Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT02363491
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Opsona Therapeutics Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT01794663
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
News
No news found